TMEM106C is overexpressed and modulates cell mobility in metastatic colon cancer cells

Year 2022, Volume: 50 Issue: 1, 77 - 84, 05.01.2022

Muzaffer Dükel

https://doi.org/10.15671/hjbc.892060

Abstract

Colon cancer is the third most commonly diagnosed cancer in men worldwide. Colon cancer grows slowly and metastasis has already occurred after diagnosis. Therefore, new targets are needed in the colon cancer treatment and diagnosis. Transmembrane proteins (TMEM) play a critical role and presents different expression profile in variety of tumor cells. TMEM106C is a TMEM family protein, but its role on colon cancer development is unknown. In this study, we aimed to investigate TMEM106C gene in metastatic colon cancer cells. TMEM106C gene expression level was tested by western blot, qRT-PCR and immunofluorescence methods. In order to test the effect of TMEM106C in colon cancer cells, this gene has been knockdown with shRNA technology. In addition, cell invasion, migration and adhesion assays were performed to clarify whether TMEM106C knockdown has effect on colon cancer metastatic characters. Ford the first time, in this study, we showed TMEM106C is overexpressed in colon carcinoma cells. Moreover, we demonstrated that cell migration, invasion and adhesion capabilities are reduced in TMEM106C silenced cells. Furthermore, we observed that metastatic cell morphology was changed upon to TMEM106C knockdown. In conclusion, we showed that TMEM106C gene is important for colon carcinoma cells.

Keywords

Colon cancer, TMEM106C, Metastasis

Thanks

We would like to thank Prof. Dr. Hulya Ayar Kayalı (Dokuz Eylul University) for the kind gifts of colon cancer cells.

References

• F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, (2018) 394–424.
• P. Rawla, T. Sunkara, A. Barsouk, Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 14, (2019) 89–103.
• T.N. Seyfried, L.C. Huysentruyt, On the origin of cancer metastasis. Crit. Rev. Oncog. 18, (2013) 43–73. H. Dillekås, M.S. Rogers, O. Straume, Are 90% of deaths from cancer caused by metastases? Cancer Med. 8, (2019) 5574–5576.
• J.A. Joyce, J.W. Pollard, Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 9, (2009) 239–252. S. Sakamoto, N. Kyprianou, Targeting anoikis resistance in prostate cancer metastasis. Mol. Aspects Med. 31, (2010) 205–214.
• G. Bendas, L. Borsig, Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol. 2012, (2012) 676731.
• U. Cavallaro, G. Christofori, Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim. Biophys. Acta. 1552, (2001), 39–45.
• K. Schmit, C. Michiels, TMEM Proteins in Cancer: A Review, Frot Pharmacol. 9, (2018) 1345. S. Marx, T. Dal Maso, J.-W. Chen, M. Bury, J. Wouters, C. Michiels, B. Le Calvé, Transmembrane (TMEM) protein family members: Poorly characterized even if essential for the metastatic process. Semin. Cancer Biol. 60, (2020) 96–106.
• S. Hrašovec, N. Hauptman, D. Glavač, F. Jelenc, M. Ravnik-Glavač, TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer. Dis. Markers. 34, (2013) 93–104.
• Y. Wang, Y. Zhang, J.G. Herman, E. Linghu, M. Guo, Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development. Oncotarget. 8, (2017) 70035–70048.
• W. Qiao, Y. Han, W. Jin, M. Tian, P. Chen, J. Min, H. Hu, B. Xu, W. Zhu, L. Xiong, Q. Lin, Overexpression and biological function of TMEM48 in non-small cell lung carcinoma. Tumour Biol. 37, (2016) 2575–2586.
• L. Flamant, E. Roegiers, M. Pierre, A. Hayez, C. Sterpin, O. De Backer, T. Arnould, Y. Poumay, C. Michiels, TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 12, (2012) 391.
• J. Guo, L. Chen, N. Luo, W. Yang, X. Qu, Z. Cheng, Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol. Rep. 33, (2015) 3124–3130.
• X. Luo, G. Han, R. Lu, S. Guan, Y. Wang, L. Ju, L. Chen, J. Shao, Z. Bian, Transmembrane protein 106C promotes the development of hepatocellular carcinoma. J. Cell. Biochem. 121, (2020) 4484-4495.
• D. Xu, L. Qu, J. Hu, G. Li, P. Lv, D. Ma, M. Guo, Y. Chen, Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis. J. Cell. Mol. Med. 18, (2014) 1655–1666.
• C. Wu, J. Xu, H. Wang, J. Zhang, J. Zhong, X. Zou, Y. Chen, G. Yang, Y. Zhong, D. Lai, X. Li, A. Tang, TMEM106a is a Novel Tumor Suppressor in Human Renal Cancer. Kidney Blood Press. Res. 42, (2017), 853–864.
• R. Vass, E. Ashbridge, F. Geser, W.T. Hu, M. Grossman, D. Clay-Falcone, L. Elman, L. McCluskey, V.M.Y. Lee, V.M. Van Deerlin, J.Q. Trojanowski, A.S. Chen-Plotkin, Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 121, (2011) 373–380.
• N.J. Rutherford, M.M. Carrasquillo, M. Li, G. Bisceglio, J. Menke, K.A. Josephs, J.E. Parisi, R.C. Petersen, N.R. Graff-Radford, S.G. Younkin, D.W. Dickson, R. Rademakers, TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology. 79, (2012) 717–718.
• J. Duan, Y. Qian, X. Fu, M. Chen, K. Liu, H. Liu, J. Yang, C. Liu, Y. Chang, TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging (Albany. NY). 13, (2021) 1-22.
• M. Dükel, W.S. Streitfeld, T.C.C. Tang, L. R.F. Backman, L. Ai, W.S. May, K.D. Brown, The breast cancer tumor suppressor TRIM29 is expressed in an ATM-dependent manner in response to hypoxia. 291, (2016) 21541–21552.
• K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-ΔΔCT) method. Methods. 25, (2001), 402–408.
• C.A.J. Portera, R.S. Berman, L.M. Ellis, Molecular determinants of colon cancer metastasis. Surg. Oncol. 7, (1998) 183–195.
• M. Xiao, H. Li, S. Yang, Y. Huang, S. Jia, H. Wang, J. Wang, Z. Li, Expression of MAC30 protein is related to survival and clinicopathological variables in breast cancer. J. Surg. Oncol. 107, (2013) 456–462.
• X. Zhou, N.C. Popescu, G. Klein, S. Imreh, The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma. Cancer Genet. Cytogenet. 177, (2007) 6–15.
• B.M. Schwenk, C.M. Lang, S. Hogl, S. Tahirovic, D. Orozco, K. Rentzsch, S.F. Lichtenthaler, C.C. Hoogenraad, A. Capell, C. Haass, D. Edbauer, The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J. 33, (2014) 450–467.
• X. Li, R. Feng, C. Huang, H. Wang, J. Wang, Z. Zhang, H. Yan, T. Wen, MicroRNA-351 regulates TMEM 59 (DCF1) expression and mediates neural stem cell morphogenesis. RNA Biol. 9, (2012) 292–301.
• J. Behrens, The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res. Treat. 24, (1993) 175–184.